Suchergebnisse - "Interferon beta-1a"

A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.

Autoren: Simone M Palumbi R Achille M et al.

Quelle: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2025 Oct; Vol. 46 (10), pp. 5391-5400. Date of Electronic Publication: 2025 Aug 08.

Publikationsart: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III; Pragmatic Clinical Trial; Comparative Study

Info zur Zeitschrift: Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100959175 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1590-3478 (Electronic) Linking ISSN: 15901874 NLM ISO Abbreviation: Neurol Sci Subsets: MEDLINE

MeSH-Schlagworte: Glatiramer Acetate*/adverse effects , Glatiramer Acetate*/administration & dosage , Glatiramer Acetate*/therapeutic use , Glatiramer Acetate*/pharmacology , Interferon beta-1a*/adverse effects , Interferon beta-1a*/administration & dosage , Interferon beta-1a*/therapeutic use , Interferon beta-1a*/pharmacology , Multiple Sclerosis*/drug therapy , Multiple Sclerosis*/diagnostic imaging , Immunologic Factors*/administration & dosage , Immunologic Factors*/adverse effects, Humans ; Female ; Male ; Child ; Adolescent ; Treatment Outcome ; Injections, Subcutaneous ; Prospective Studies ; Injections, Intramuscular ; Quality of Life

Beta Interferon 1a and Laquinimod Differentially Affect Coagulation-Related Gene Expression in Multiple Sclerosis Patients: Implications for Clinical Efficacy and Side Effects.

Autoren: Gurevich M Zilkha-Falb R Chapman J et al.

Quelle: International journal of molecular sciences [Int J Mol Sci] 2025 Nov 17; Vol. 26 (22). Date of Electronic Publication: 2025 Nov 17.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

MeSH-Schlagworte: Quinolones*/therapeutic use , Quinolones*/pharmacology , Quinolones*/adverse effects , Blood Coagulation*/drug effects , Blood Coagulation*/genetics , Interferon beta-1a*/therapeutic use , Interferon beta-1a*/pharmacology , Interferon beta-1a*/adverse effects , Gene Expression Regulation*/drug effects , Multiple Sclerosis*/drug therapy , Multiple Sclerosis*/genetics , Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/genetics, Humans ; Adult ; Male ; Female ; Middle Aged ; Leukocytes, Mononuclear/metabolism ; Leukocytes, Mononuclear/drug effects ; Plasminogen Activator Inhibitor 1/genetics ; Plasminogen Activator Inhibitor 1/metabolism ; Fibrinolysis/drug effects ; Fibrinolysis/genetics

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.

Autoren: Hua LH Hersh CM Zhovtis Ryerson L et al.

Quelle: Neurodegenerative disease management [Neurodegener Dis Manag] 2025 Oct; Vol. 15 (5), pp. 199-207. Date of Electronic Publication: 2025 Jul 15.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101517977 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1758-2032 (Electronic) Linking ISSN: 17582024 NLM ISO Abbreviation: Neurodegener Dis Manag Subsets: MEDLINE

MeSH-Schlagworte: Interferon beta-1a*/therapeutic use , Interferon-beta*/therapeutic use , Multiple Sclerosis*/drug therapy , Polyethylene Glycols*/therapeutic use , Immunologic Factors*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Treatment Outcome ; Disease Progression ; Age Factors

Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ-1a Biologics to Inform Potential Utility in Biosimilar Development.

Autoren: Chekka LMS Samarth DP Guo Y et al.

Quelle: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2025 Oct; Vol. 118 (4), pp. 935-945. Date of Electronic Publication: 2025 Jul 04.

Publikationsart: Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

MeSH-Schlagworte: Biosimilar Pharmaceuticals*/administration & dosage , Biosimilar Pharmaceuticals*/pharmacokinetics , Biosimilar Pharmaceuticals*/pharmacology , Proteomics*/methods , Interferon beta-1a*/administration & dosage , Interferon beta-1a*/pharmacokinetics , Interferon beta-1a*/pharmacology , Interferon-beta*/administration & dosage , Interferon-beta*/pharmacokinetics , Interferon-beta*/pharmacology , Polyethylene Glycols*/administration & dosage , Polyethylene Glycols*/pharmacokinetics , Polyethylene Glycols*/pharmacology, Humans ; Male ; Biomarkers/blood ; Female ; Adult ; Dose-Response Relationship, Drug ; Young Adult ; Middle Aged ; Drug Development/methods ; Biomarkers, Pharmacological/blood

Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.

Autoren: Hersh CM Aladro-Benito Y Lewin JB et al.

Quelle: Journal of comparative effectiveness research [J Comp Eff Res] 2025 Oct; Vol. 14 (10), pp. e250061. Date of Electronic Publication: 2025 Sep 12.

Publikationsart: Comparative Study; Journal Article

Info zur Zeitschrift: Publisher: Becaris Publishing Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/therapeutic use , Immunologic Factors*/therapeutic use , Interferon beta-1a*/therapeutic use , Multiple Sclerosis, Relapsing-Remitting*/drug therapy, Adult ; Female ; Humans ; Male ; Middle Aged ; Disease Progression ; Double-Blind Method ; Treatment Outcome ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic ; Fumarates

Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.

Autoren: Kappos L Yiu S Reucassel J et al.

Quelle: Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2025 Sep; Vol. 12 (9), pp. 1805-1812. Date of Electronic Publication: 2025 Jul 08.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Periodicals, Inc on behalf of American Neurological Association Country of Publication: United States NLM ID: 101623278 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2328-9503 (Electronic) Linking ISSN: 23289503 NLM ISO Abbreviation: Ann Clin Transl Neurol Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/pharmacology , Antibodies, Monoclonal, Humanized*/administration & dosage , Disease Progression* , Immunologic Factors*/pharmacology , Immunologic Factors*/administration & dosage , Interferon beta-1a*/pharmacology , Interferon beta-1a*/administration & dosage , Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/diagnosis , Multiple Sclerosis, Relapsing-Remitting*/physiopathology , Multiple Sclerosis, Relapsing-Remitting*/blood , Outcome Assessment, Health Care*/standards, Adult ; Female ; Humans ; Male ; Middle Aged ; Disability Evaluation ; Magnetic Resonance Imaging ; Neurofilament Proteins/blood ; Recurrence ; Severity of Illness Index ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic

Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.

Autoren: Benedict RH Kappos L Miller A et al.

Quelle: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2025 Mar; Vol. 95, pp. 106310. Date of Electronic Publication: 2025 Feb 02.

Publikationsart: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/pharmacology , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/complications , Interferon beta-1a*/pharmacology , Interferon beta-1a*/therapeutic use , Interferon beta-1a*/administration & dosage , Immunologic Factors*/pharmacology , Immunologic Factors*/administration & dosage , Immunologic Factors*/therapeutic use , Cognitive Dysfunction*/etiology , Cognitive Dysfunction*/drug therapy, Humans ; Adult ; Male ; Female ; Middle Aged ; Double-Blind Method

Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).

Autoren: Shaygannejad V Ashtari F Saeidi M et al.

Quelle: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Oct; Vol. 90, pp. 105839. Date of Electronic Publication: 2024 Aug 20.

Publikationsart: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Comparative Study; Equivalence Trial

Info zur Zeitschrift: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE

MeSH-Schlagworte: Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Interferon beta-1a*/administration & dosage , Interferon beta-1a*/pharmacology , Interferon beta-1a*/adverse effects , Polyethylene Glycols*/administration & dosage , Polyethylene Glycols*/adverse effects , Polyethylene Glycols*/pharmacology, Humans ; Adult ; Male ; Female ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Immunologic Factors/pharmacology ; Middle Aged ; Interferon-beta/administration & dosage ; Interferon-beta/adverse effects ; Interferon-beta/pharmacology ; Young Adult

Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement.

Autoren: Swart ECS Peasah SK Alderson J et al.

Quelle: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2024 Nov; Vol. 30 (11), pp. 1211-1216.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Academy of Managed Care Pharmacy Country of Publication: United States NLM ID: 101644425 Publication Model: Print Cited Medium: Internet ISSN: 2376-1032 (Electronic) Linking ISSN: 23760540 NLM ISO Abbreviation: J Manag Care Spec Pharm Subsets: MEDLINE

MeSH-Schlagworte: Multiple Sclerosis*/drug therapy , Disease Progression* , Patient Reported Outcome Measures* , Dimethyl Fumarate*/therapeutic use , Interferon beta-1a*/therapeutic use, Humans ; Male ; Female ; Prospective Studies ; Adult ; Middle Aged ; United States ; Disability Evaluation

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons.

Autoren: Jiang T Shanmugasundaram M Božin I et al.

Quelle: Journal of comparative effectiveness research [J Comp Eff Res] 2024 Oct; Vol. 13 (10), pp. e230161. Date of Electronic Publication: 2024 Aug 19.

Publikationsart: Journal Article; Comparative Study; Clinical Trial, Phase III; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Becaris Publishing Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE

MeSH-Schlagworte: Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Interferon beta-1a*/therapeutic use , Oxadiazoles*/therapeutic use, Humans ; Female ; Male ; Adult ; Indans/therapeutic use ; Middle Aged ; Dimethyl Fumarate/therapeutic use ; Double-Blind Method ; Treatment Outcome ; Disease Progression

Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials.

Autoren: Dzau W Roos I Kalincik T

Quelle: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2025 Sep 12; Vol. 96 (10), pp. 953-959. Date of Electronic Publication: 2025 Sep 12.

Publikationsart: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 2985191R Publication Model: Electronic Cited Medium: Internet ISSN: 1468-330X (Electronic) Linking ISSN: 00223050 NLM ISO Abbreviation: J Neurol Neurosurg Psychiatry Subsets: MEDLINE

MeSH-Schlagworte: Natalizumab*/therapeutic use , Multiple Sclerosis, Chronic Progressive*/drug therapy , Immunologic Factors*/therapeutic use , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Male ; Female ; Disease Progression ; Adult ; Middle Aged ; Treatment Outcome ; Interferon beta-1a/therapeutic use ; Double-Blind Method ; Proportional Hazards Models

Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.

Autoren: Signori A Ponzano M Kalincik T et al.

Quelle: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2024 Jun 17; Vol. 95 (7), pp. 620-625. Date of Electronic Publication: 2024 Jun 17.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 2985191R Publication Model: Electronic Cited Medium: Internet ISSN: 1468-330X (Electronic) Linking ISSN: 00223050 NLM ISO Abbreviation: J Neurol Neurosurg Psychiatry Subsets: MEDLINE

MeSH-Schlagworte: Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Fingolimod Hydrochloride*/therapeutic use , Interferon beta-1a*/therapeutic use , Registries* , Randomized Controlled Trials as Topic*, Humans ; Male ; Female ; Adult ; Middle Aged ; Immunosuppressive Agents/therapeutic use ; Treatment Outcome

Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.

Autoren: Harris S Comi G Cree BAC et al.

Quelle: European journal of neurology [Eur J Neurol] 2025 Jun; Vol. 32 (6), pp. e70222.

Publikationsart: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE

MeSH-Schlagworte: Glial Fibrillary Acidic Protein*/blood , Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/blood , Oxadiazoles*/therapeutic use , Oximes*/therapeutic use , Sphingosine 1 Phosphate Receptor Modulators*/therapeutic use, Adult ; Female ; Humans ; Male ; Middle Aged ; Biomarkers/blood ; Interferon beta-1a/therapeutic use ; Treatment Outcome ; Indans

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Autoren: Arnold DL Kolind S Assemlal HE et al.

Quelle: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2025 Jun; Vol. 31 (7), pp. 821-832. Date of Electronic Publication: 2025 Apr 16.

Publikationsart: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/pharmacology , Cerebellum*/drug effects , Cerebellum*/pathology , Cerebellum*/diagnostic imaging , Immunologic Factors*/administration & dosage , Immunologic Factors*/pharmacology , Multiple Sclerosis, Chronic Progressive*/drug therapy , Multiple Sclerosis, Chronic Progressive*/pathology , Multiple Sclerosis, Chronic Progressive*/diagnostic imaging , Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/pathology , Multiple Sclerosis, Relapsing-Remitting*/diagnostic imaging, Adult ; Female ; Humans ; Male ; Middle Aged ; Double-Blind Method ; Interferon beta-1a/administration & dosage ; Magnetic Resonance Imaging ; Time Factors ; Treatment Delay

[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].

Transliterierter Titel: Dolgosrochnye dannye po effektivnosti i bezopasnosti preparata sampeginterferon-β1a u patsientov s remittiruyushchim rasseyannym sklerozom: rezul'taty 104-nedel'nogo randomizirovannogo dvoinogo slepogo klinicheskogo issledovaniya.

Autoren: Boyko AN Bakhtiyarova KZ Boyko OV et al.

Quelle: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (2), pp. 52-59.

Publikationsart: Randomized Controlled Trial; English Abstract; Journal Article

Info zur Zeitschrift: Publisher: Media Sfera Country of Publication: Russia (Federation) NLM ID: 9712194 Publication Model: Print Cited Medium: Print ISSN: 1997-7298 (Print) Linking ISSN: 19977298 NLM ISO Abbreviation: Zh Nevrol Psikhiatr Im S S Korsakova Subsets: MEDLINE

MeSH-Schlagworte: Interferon beta-1a*/administration & dosage , Interferon beta-1a*/adverse effects , Interferon beta-1a*/therapeutic use , Multiple Sclerosis, Relapsing-Remitting*/diagnostic imaging , Multiple Sclerosis, Relapsing-Remitting*/drug therapy, Humans ; Double-Blind Method ; Multiple Sclerosis/drug therapy ; Recurrence ; Treatment Outcome ; Adolescent ; Young Adult ; Adult ; Middle Aged

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.

Autoren: Cerqueira JJ Berthele A Cree BAC et al.

Quelle: Neurology [Neurology] 2025 Feb 25; Vol. 104 (4), pp. e210142. Date of Electronic Publication: 2025 Jan 30.

Publikationsart: Journal Article; Randomized Controlled Trial; Multicenter Study

Info zur Zeitschrift: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE

MeSH-Schlagworte: Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/diagnostic imaging , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Immunologic Factors*/therapeutic use , Immunologic Factors*/adverse effects, Humans ; Female ; Male ; Adult ; Double-Blind Method ; Middle Aged ; Treatment Outcome ; Interferon beta-1a/therapeutic use ; Magnetic Resonance Imaging ; Disease Progression

Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis.

Autoren: Rezaee M Ravangard R Mojtabaeian SM et al.

Quelle: BMC health services research [BMC Health Serv Res] 2024 Oct 28; Vol. 24 (1), pp. 1288. Date of Electronic Publication: 2024 Oct 28.

Publikationsart: Comparative Study; Journal Article; Systematic Review

Info zur Zeitschrift: Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963 (Electronic) Linking ISSN: 14726963 NLM ISO Abbreviation: BMC Health Serv Res Subsets: MEDLINE

MeSH-Schlagworte: Fingolimod Hydrochloride*/therapeutic use , Fingolimod Hydrochloride*/economics , Fingolimod Hydrochloride*/administration & dosage , Multiple Sclerosis, Relapsing-Remitting*/drug therapy , Multiple Sclerosis, Relapsing-Remitting*/economics , Cost-Effectiveness Analysis*, Humans ; Administration, Oral ; Alemtuzumab/administration & dosage ; Alemtuzumab/therapeutic use ; Alemtuzumab/economics ; Crotonates/therapeutic use ; Crotonates/administration & dosage ; Crotonates/economics ; Hydroxybutyrates ; Immunosuppressive Agents/economics ; Immunosuppressive Agents/therapeutic use ; Immunosuppressive Agents/administration & dosage ; Injections ; Interferon beta-1a/therapeutic use ; Interferon beta-1a/administration & dosage ; Interferon beta-1a/economics ; Nitriles/economics ; Nitriles/therapeutic use ; Nitriles/administration & dosage ; Toluidines/therapeutic use ; Toluidines/administration & dosage ; Toluidines/economics

Switching from injectable to other Disease Modifying Therapies may improve sexual dysfunction in people with Multiple Sclerosis.

Autoren: Ala S Amirkafi A Kohandel K et al.

Quelle: BMC neurology [BMC Neurol] 2024 Jul 24; Vol. 24 (1), pp. 255. Date of Electronic Publication: 2024 Jul 24.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: BioMed Central Country of Publication: England NLM ID: 100968555 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2377 (Electronic) Linking ISSN: 14712377 NLM ISO Abbreviation: BMC Neurol Subsets: MEDLINE

MeSH-Schlagworte: Multiple Sclerosis*/drug therapy , Multiple Sclerosis*/complications , Sexual Dysfunction, Physiological*/etiology , Sexual Dysfunction, Physiological*/drug therapy , Glatiramer Acetate*/administration & dosage , Glatiramer Acetate*/therapeutic use, Humans ; Female ; Adult ; Middle Aged ; Longitudinal Studies ; Young Adult ; Immunologic Factors/administration & dosage ; Immunologic Factors/therapeutic use ; Dimethyl Fumarate/administration & dosage ; Dimethyl Fumarate/therapeutic use ; Adolescent ; Immunosuppressive Agents/therapeutic use ; Immunosuppressive Agents/administration & dosage ; Interferon beta-1a/administration & dosage ; Interferon beta-1a/therapeutic use ; Drug Substitution/methods ; Fingolimod Hydrochloride/therapeutic use ; Fingolimod Hydrochloride/administration & dosage ; Natalizumab/administration & dosage ; Natalizumab/therapeutic use

Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled study.

Autoren: Hakovirta H Jalkanen J Saimanen E et al.

Körperschaften: Hakovirta H Jalkanen J Saimanen E et al.

Quelle: Scientific reports [Sci Rep] 2022 Feb 03; Vol. 12 (1), pp. 1839. Date of Electronic Publication: 2022 Feb 03.

Publikationsart: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Info zur Zeitschrift: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

MeSH-Schlagworte: Vascular Surgical Procedures*/adverse effects , Vascular Surgical Procedures*/mortality, 5'-Nucleotidase/*metabolism , Adjuvants, Immunologic/*therapeutic use , Aortic Aneurysm, Abdominal/*therapy , Aortic Rupture/*therapy , Interferon beta-1a/*therapeutic use, Adjuvants, Immunologic/adverse effects ; Administration, Intravenous ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/blood ; Aortic Aneurysm, Abdominal/immunology ; Aortic Aneurysm, Abdominal/metabolism ; Aortic Aneurysm, Abdominal/mortality ; Aortic Rupture/diagnosis ; Aortic Rupture/immunology ; Aortic Rupture/mortality ; Double-Blind Method ; Drug Interactions ; Early Termination of Clinical Trials ; Emergencies ; Female ; Finland ; GPI-Linked Proteins/metabolism ; Glucocorticoids/adverse effects ; Humans ; Interferon beta-1a/adverse effects ; Interferon beta-1a/immunology ; Male ; Risk Factors ; Time Factors ; Treatment Outcome ; Up-Regulation

Transformative Years of BIOSIMILARS.

Quelle: BioSpectrum. May2025, Vol. 23 Issue 5, p17-21. 5p.

Schlagwörter: INTERFERON beta-1a, GRANULOCYTE-colony stimulating factor, MACROPHAGE colony-stimulating factor, DRUG standards, TERIPARATIDE, MONOCLONAL antibodies, GUIDED tissue regeneration